EU/3/15/1445

About

On 12 February 2015, orphan designation (EU/3/15/1445) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for ulocuplumab for the treatment of acute myeloid leukaemia.

The sponsor’s address was updated in July 2019.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.

Key facts

Active substance
Ulocuplumab
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
12/02/2015
Outcome
Withdrawn
EU designation number
EU/3/15/1445

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland
Tel: +353 1 483 3857
E-mail: eeig@bms.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating